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Objective: To compare biologics as monotherapy or in combination with methotrexate (MTX) in terms of patient
reported outcomes (PROs) in RA patients with an inadequate response to conventional DMARDs (DMARD-IR).
Methods: With a systematic literature review 17 RCTs were identified that evaluated adalimumab, certolizumab
pegol, etanercept, golimumab, infliximab, abatacept, anakinra or tocilizumab. Treatment effects in terms of pain
(0-100 mm), patient’s global assessment of disease activity (PGA; 0-100 mm), Health Assessment-Questionnaire
(HAQ) disability index (DI; 0–3), and the physical component summary (PCS) of the SF36 Health Survey (0–100)
at 24 weeks were combined by means of Bayesian network meta-analyses.
Results: With tocilizumab monotherapy, greater improvements in pain (difference = −11.1; (95% Credible
Interval −21.3, −0.1)) and PGA (−10.3 (−20.4, 0.8)) were observed than with aTNF monotherapy. Tocilizumab was at
least as efficacious as aTNF in HAQ-DI improvements (−0.16; (−0.37, 0.05)). aTNF +MTX (−17.9 (−23.1, −13.0) & -19.1
(−24.2, −14.4)), abatacept + MTX (−23.0 (−47.3, 1. 5) & -13.6 (−28.4, 2.0)) and tocilizumab + MTX (−16.0 (−26.3, −6.3)
& -15.1 (−25.1, −5.7)) showed comparable reductions in pain and PGA relative to MTX. Efficacy of anakinra + MTX
was much smaller as compared to other biologics. The greatest improvements in HAQ-DI relative to MTX were
observed with aTNF +MTX (−0.30 (−0.37, −0.22)) and tocilizumab + MTX (−0.27 (−0.42, −0.12)), followed by
abatacept + MTX (−0.21 (−0.37, −0.05)) and anakinra + MTX (−0.11 (−0.26, 0.05)). The improvements in SF36-PCS
with abatacept + MTX, aTNF + MTX and tocilizumab +MTX were comparable. There is a >90% probability that
aTNF +MTX results in a greater improvement in pain (−12.4), PGA (−16.1) and HAQ-DI (−0.21) than aTNF as monotherapy.
Efficacy of tocilizumab +MTX showed comparable improvements in PROs as tocilizumab monotherapy.
Conclusions: Based on a network meta-analysis involving indirect comparison of trial findings, the following observations
were made for DMARD-IR patients. In monotherapy, tocilizumab was associated with a greater improvement in pain and
self-reported disease activity than aTNF, and was at least as efficacious regarding functional ability. The improvements in
PROs with aTNF, abatacept and tocilizumab in combination with MTX were comparable. Improvements in PROs with
tocilizumab as monotherapy were similar to that of tocilizumab +MTX, whereas aTNF as monotherapy was likely to be
less efficacious than aTNF +MTX.
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Rheumatoid arthritis (RA) is a chronic inflammatory
joint disorder characterised by joint stiffness, swelling,
and pain, and can have a profound impact on a patient’s
health related quality of life [1,2]. As such, the goals of
treatment of RA are not only symptom relief, reduction
in disease activity, and reduction in the rate of joint
damage, but also improvement in physical functioning
and well-being from the patient’s perspective [3,4].
The European League Against Rheumatism (EULAR),
American College of Rheumatology (ACR), and Outcomes
Measures in Rheumatology (OMERACT) have outlined
the importance of patient reported outcomes (PROs) in
addition to physician assessed outcomes for the complete
assessment of progression of disease and the evaluation of
the effectiveness of RA treatment [5]. PROs used for the
assessment of treatments in RA clinical trials typically
include pain, patient's global assessment of disease
activity (PGA), and the general health measures Health
Assessment-Questionnaire (HAQ) disability index (DI)
and Medical Outcomes Study Short Form 36 Health
Survey (SF36) [6-8].
Patients who are intolerant or show an inadequate
response (IR) to traditional disease-modifying anti-
rheumatic drugs (DMARDs) are often treated with a
biologic agent. For DMARD-IR patients, biologics are
usually combined with traditional DMARDs, primarily
methotrexate (MTX), but some biologics are approved
and have been shown to be efficacious as monotherapy as
well [9-11]. In real life, approximately one-third of
RA patients on biologics are on monotherapy [12-14].
Given the number of the alternative biologic treatment
options for the DMARD-IR RA population, clinicians
are faced with a challenging choice regarding the optimal
treatment. There is no randomized controlled trial (RCT)
that evaluates all approved biologics simultaneously to
help answer this question. The available evidence base
consists of multiple placebo controlled trials and some
active head-to-head comparisons. Network meta-analysis
has been introduced, as a generalisation of pair-wise
meta-analysis, to simultaneously synthesize the different
RCTs evaluating different biologics and perform indirect
comparisons in the absence of head-to-head studies. In
the past few years several network meta-analysis of
biologic treatments for RA have been published [15-22].
However, currently there is no network meta-analysis that
compares the treatment effects of combination therapy
and monotherapy regarding PROs.
The objective of the current study was to compare the
efficacy of biologic DMARDs used as monotherapy or in
combination with MTX in terms of pain, self-reported
disease activity, functional ability, and overall health
related Quality of Life (HRQoL) among DMARD-IR RA
patients based on currently available evidence from RCTs.Methods
Identification and selection of studies and data extraction
The following criteria for considering published studies
for review were used:
 Population of interest: DMARD-IR RA patients.
 Interventions: tocilizumab, TNF-blockers, abatacept,
and anakinra in their usual dose, alone and in
combination with conventional DMARDs. Rituximab
was not considered because its label is restricted to
TNF-IR patients. Tofacitinib was not included because
it was not approved at the time of this study.
 Comparisons: Placebo or one of the regimes
described under interventions. Comparisons of
different dosages of the same intervention only, or
comparison of the same interventions with different
background treatments were excluded.
 Outcomes/endpoints: HAQ-DI, Pain, PGA, SF36,
and fatigue.
 Study design: randomized controlled trials
 Exclusion: Studies with solely Asian patients, and
non-English language publications were excluded.
The pre-defined search strategy of the Medline, Embase,
and Cochrane databases used terms related to RA,
biologics, and RCTs to allow for a systematic search
of studies published between 1990 and April 2012
(See Appendix for search strategy). Titles and abstracts
were screened to ascertain whether studies met predefined
selection criteria. Studies that either met the criteria or for
which it was unclear were further screened using the full
text report.
For each identified study that met the selection criteria,
details were extracted on study design, study population
characteristics, study quality according to the Jadad
criteria [23], interventions, and the outcomes pain, PGA,
HAQ-DI, and SF36. Pain and PGA were assessed on 0 to
100 mm visual analog scale (VAS); higher scores reflect
greater pain and disease activity and minimum clinically
important differences (MCIDs) are ≥10 mm increase
from baseline [24-28]. HAQ-DI assesses the level of
an individual’s functional ability and scores range from 0
to 3; higher scores indicate more severe disability and the
MCID is a ≥ 0.22 points increase [25]. The SF36 yields 8
domain scores which are summarized in a physical health
component summary (PCS) score and mental health
component summary (MCS) score. The scale ranges
from 0 to 100 with higher scores reflecting greater
HRQoL. Improvements of ≥ 5 points from baseline
represent a MCID [7,8].
Network meta-analysis
To synthesize the results of the included studies, Bayesian
network meta-analysis models were used [29-32]. For the
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analysis demonstrated that the different aTNFs are
exchangeable [19,20]. Within a Bayesian framework,
analysis involves data, a likelihood distribution, a model
with parameters, and prior distributions for these
parameters [33]. A regression model with a normal
likelihood distribution relates the data from the individual
studies to basic parameters reflecting the (pooled)
treatment effect of each intervention compared to
placebo. Based on these basic parameters, the relative
efficacy between each of the compared biologics, as
monotherapy and combination was calculated.
Both fixed and random effects models were considered
and were compared regarding the goodness-of-fit to the
data, calculated as the posterior mean residual deviance.
The deviance information criterion (DIC) provides a
measure of model fit that penalizes model complexity
[34]. The random effects model resulted in the lowest
DIC, and was considered appropriate for the synthesis of
the available evidence.
To avoid influence of the prior distributions required
for the Bayesian analyses on results, non-informative
prior distributions were used. Prior distributions of the
treatment effects relative to placebo were normal
distributions with mean 0 and a variance of 10,000. A
uniform distribution with range of 0–20 (pain, PGA, SF36)
and 0–6 (HAQ) was used for the prior distribution of
heterogeneity needed for the random effects analyses.
WinBUGS statistical software was used for the analyses
[35]. The results of the network meta-analysis provide us
with posterior distributions of treatment effects of each
treatment versus placebo in terms of difference in change
from baseline. In order to transform these difference
measures into an expected change from baseline with
each treatment, the effect estimates of each regimen
relative to placebo were combined with the average
change from baseline with placebo across studies. The
posterior distributions of the treatment effect (i.e. difference
in change from baseline) and expected change from
baseline by treatment were summarized with the median
and 95% credible intervals (95% CI) reflecting the range of
true underlying effects with 95% probability. Based on the
posterior distributions of relative treatment effects the
probability that a certain intervention was more efficacious
than a competitor was calculated, as well the probability
that each treatment ranks 1st, 2nd, 3rd, etc. The latter
findings were expressed with rankograms.
Results
Study identification
The literature search resulted in 1,217 unique, potentially
relevant citations, of which abstract review excluded 1,060
(87%) (Figure 1). Of the remaining 157 retrieved full
text publications, 133 (11%) were excluded throughthe full-text review. A total of 26 full text reports
corresponding to 20 different RCTs, including 2 studies
provided by Roche (ACT-RAY and ADACTA) met the
selection criteria [9-11,36-56]. These 2 latest studies
were not published at the time of the data cut, but
were considered crucial for the evidence network.
Evidence base
Most of the trials were multi-centred and included
patients predominantly from Europe and North America.
The RCTs were generally considered to be good quality
(Jadad score range 3–5). All included trials were double
blind with appropriate description of drop out of subjects,
although the method of randomisation and blinding was
not always reported. The majority of the studies included
adult patients with diagnosis of RA based on the
ACR 1987 revised classification criteria. All studies
included DMARD-IR patients. Although the definition
of DMARD-IR varied somewhat between the studies,
it was most commonly defined as patients with active
disease despite of previous treatment with traditional
DMARDs. The traditional DMARD was often specified to
be MTX, although in fewer studies it was unspecified.
Other definitions included inadequate response to prior
DMARDs, or patients who are either intolerant to MTX,
or the use of MTX is inappropriate. The TEMPO trial
included patients who were non-responders to DMARDs
but disqualified patients who had failed MTX treatment
[52]. Given this difference, the study was excluded from
the network meta-analysis. The definitions of active
disease varied in terms of the minimum levels of ESR
(10 mm/h, 28 mm/h) and CRP (2 mg/dl, 1 mg/dl,
1.5 mg/dl, 7 mg/ml), as well as in terms of the minimum
number of required tender [6-12] and swollen [6-12] joints.
Not all studies reported whether RA disease duration and
DMARD treatment duration determined eligibility.
In RCTs evaluating the efficacy of biologics in combin-
ation with a traditional DMARD, MTX was the back-
ground treatment of choice, except for the study by
Combe et al. in which sulfasalazine was used [37,38]. To
allow a valid indirect comparison between treatments
with the network meta-analysis, this study was excluded
as well. The study by Schiff et al. was also excluded
because no results at 24 weeks were provided for the
outcomes of interest [48].
Thirteen studies, including ACT-RAY and ADACTA,
provided outcome data for pain and PGA [9,11,36,
39,41,44,49-51,54,55]. All seventeen studies provided
information on HAQ-DI. Eight studies (including
ADACTA) provided information on the SF36 PFS
[9,40,44,47,49-51], but 2 of these studies (ADACTA and
Matthias 2000) could not be used for the network
meta-analysis because these studies could not be linked to
the network of RCTs. The number of studies providing



















24 publications included from literature 
describing 18 different RCTs
2 studies by sponsor
26 full text reports corresponding to 20 
different RCTs
22 full text reports corresponding to17
different RCTs included in network meta-
analysis
1 study not MTX-IR 
1 study (2 publications): no MTX as 
background treatment
1 study no outcomes data at 24/26 
weeks
Figure 1 Flow diagram of study identification and selection.
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network meta-analysis. Nine studies (including ADACTA)
reported fatigue as an outcome measure, but given
differences in the instruments used (i.e. Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-F),
Fatigue Assessment Scale (FAS), and Fatigue VAS) a
network meta-analysis was not considered feasible
[39,40,43,47,49-51,56].Figure 2 Network of randomized controlled trials evaluating agents fIn Figure 2 the network of the 17 RCTs is presented
where each line between nodes reflects the available
direct comparisons. By means of network meta-
analysis a treatment effect of each intervention rela-
tive to another that is part of the same network can
be obtained.
Table 1 provides information on the study and patient
characteristics of the 17 RCTs used for the networkor DMARD-IR RA patients in terms of PROs at 24 weeks.
Table 1 Study and patient baseline characteristics of studies included in the network meta-analysis


















ABT 10 mg/kg Q4W +MTX 115 56 75 10 21.3 30.8 NR 29 90
Placebo + MTX 119 55 66 9 21.8 29.2 NR 32 90
Kremer [43],
Russell [47]
ABT 10 mg/kg Q4W +MTX 433 52 78 9 21.4 31 NR 33 82
Placebo + MTX 219 50 82 9 22.1 32.3 NR 28 79
Cohen [36]
ANA 100 mg QD +MTX 250 56 79 11 20.1 26.8 41.5 27 76
Placebo + MTX 251 57 75 10 20 24.5 42.9 26 78
Maini [46], Lipsky
[45] (ATTRACT)
IFX 3 mg/kg Q8W +MTX 86 54 81 10 22 32 49 39 84
Placebo + MTX 88 51 80 11 21 31 49 40 77
Keystone [41],
Yount [56]
ADA 40 mg QOW+MTX 207 56 76 11 19.3 27.3 NR 18 82
Placebo + MTX 200 56 73 11 19 28.1 NR 18 90
Weinblatt [54], Yount
[56] (ARMADA)
ADA 40 mg QOW+MTX 67 57 75 12 17.3 28 NR 21 NR
Placebo + MTX 62 56 82 11 16.9 28.7 NR 31 NR
Van de Putte [11]
ADA 40 mg QOW 113 53 80 11 20.5 33.7 55.8 52.6 80
Placebo 110 54 77 12 19.8 35.5 56.1 57 82
Strand [51], (RAPID 1)
CTZ 200 mg QOW+MTX 393 51 82 6 9.9 M 12.4 M 43.5 M 16 M 80
Placebo + MTX 199 52 84 6 9.7 M 13 M 45 M 16 M 83
Smolen [50], Strand
[52], (RAPID 2)
CTZ 200 mg QOW+MTX 246 52 84 6 20.5 30.1 43.7 14.2 78
Placebo + MTX 127 52 84 6 21.9 30.4 40.8 13.5 78
Fleischmann [39]
(FAST4WARD)
CTZ 400 mg Q4W 111 53 78 9 21.2 29.6 30.9 11.6 100
Placebo 109 55 89 10 19.9 28.3 35.6 11.3 100
Weinblatt [55]
ETN 25 mg BW +MTX 59 48 90 13 20 28 25 22 84
Placebo + MTX 30 53 73 13 17 28 36 26 90
Moreland [10],
Mathias [9]
ETN 25 mg BW 78 53 74 11 25 33 35 47 79
Placebo 80 51 76 12 25 35 39 41 79
Keystone [42]
(GO-FORWARD)
GLB 50 mg Q4W+MTX 89 52 M 81 4.5 M 13 M 26 M NR 10 M 81
Placebo + MTX 133 52 M 82 6.5 M 12 M 21 M NR 8 M 81
Genovese [40]
(TOWARD)
TCZ 8 mg/kg Q4W +MTX 803 53 81 10 19.7 30.1 48.2 26 NR
Placebo + MTX 413 54 84 10 18.7 29.1 49.2 26 NR
Smolen [49] (OPTION)
TCZ 8 mg/kg Q4W +MTX 205 51 NR 8 19.5 31.9 51.2 26 83
Placebo + MTX 204 51 NR 8 20.7 32.8 49.7 24 71
ACT-RAY
TCZ 8 mg/kg Q4W +MTX 277 53 81.9 8.2 14.4 25.8 39.9 NR NR
TCZ 8 mg/kg Q4W 276 53.6 78.6 8.3 15.3 26.6 39.6 NR NR
ADACTA
TCZ 8 mg/kg 163 54.4 79 7.3 11.3 15.9 50.5 26 NR
ADA 40 mg 162 53.3 82 6.3 12.4 16.5 45.5 25 NR
M=median; NR = not reported; SJC = swollen joint count; TJC = tender joint count; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein;
RF + ve = Rheumatoid factor positive ABT = abatacept; ANA = anakinra; IFX = infliximab; ADA = adalimumab; CTZ = certolizumab pegol; ETN = etanercept;
GLB = golimumab; TCZ = tocilizumab; MTX =methotrexate.
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from 48 to 57. Female patients were predominant; the
proportion of women in the study arms ranged from
66% to 90%. Disease duration ranged from 4.5 to
13 years, swollen joint count ranged from 11.3 to 21.9,
and tender joint count ranged from 13 to 35.5. The re-
ported ESR ranged from 25 to 56.1 mm/1 hr, CRP variedbetween 8 and 52.6, and rheumatoid factor positivity
ranged from 77% to 100%. Despite some variation in
patient characteristics across studies (i.e. duration of
disease, lower swollen and tender joint count, and lower
CRP), there were no observed systematic differences
across the different types of direct comparisons, indicating
the feasibility of the network meta-analysis.
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In Tables 2, 3, 4 and 5 the results of the network meta-
analysis are presented. Each cell presents the difference
in change from baseline for the outcome of interest
24 weeks with the intervention (in the rows) relative to a
comparator (in the column). Individual study results are
provided in Additional file 1: Table S1.
Both aTNF (−20.2, −17.4, −0.37) and tocilizumab
(−31.3, −27.7, −0.53) as monotherapy demonstrated
greater reductions in pain, self-reported disease activity
(PGA), and HAQ-DI scores than placebo. These improve-
ments over placebo were larger than the MCID for each
endpoint.
Tocilizumab monotherapy showed greater improve-
ments in pain (−11.1; 95% CrI −21.3, −0.1) than aTNF as
monotherapy, and can be expected to be more efficacious
in terms of PGA as well (−10.3, 95% CrI −20.4, 0.8;
probability better = 97%). Tocilizumab was at least as
efficacious as aTNF agents in HAQ-DI improvements
(−0.16; 95% CrI −0.37, 0.05; probability better = 94%).
In Figure 3 the expected reduction in pain, PGA and
HAQ-DI for each treatment as monotherapy is presented.
Given the available studies, no comparison of SF36 for the
biologics as monotherapy was possible.
Treatment in combination with methotrexate
aTNF (−17.9, −19.1), abatacept (−23.0, −13.6) and toci-
lizumab (−16.0, −15.1) in combination with MTX showed
comparable reductions in pain and PGA relative to MTX
in this DMARD-IR population (Tables 2 and 3). These
improvements over MTX are expected to be greater than
the MCID. The reduction in pain and PGA with anakinra
(−7.3, −8.7) was smaller.
Regarding HAQ-DI, the greatest improvements over
MTX can be expected with aTNF (−0.30) and tocilizumab
(−0.27), both clinically meaningful, followed by abatacept
(−0.21) and anakinra (−0.11) (Table 4). Improvements
in physical health according to the SF36-PCS with
abatacept, aTNF and tocilizumab were comparable
(Table 5).
Comparison of monotherapy and treatment in
combination with methotrexate
There is a 93% and 96% probability that aTNF in
combination with MTX results in a greater reduction in
pain (−12.4) and PGA (−16.1) than aTNF as monotherapy.
These differences are expected to be greater than the
MCID. For HAQ-DI there is a 92% chance that aTNF with
MTX is more efficacious than aTNF as monotherapy
(−0.21). For tocilizumab however, the improvement in
pain, PGA, and HAQ-DI with and without MTX was
comparable at 24 weeks.
Figure 4 presents the probability that each interven-
tion is ranked as 1st, 2nd, 3rd etc. out of all interventionscompared for each outcome based on estimated treat-
ment effects and associated uncertainty. These ranko-
grams summarize the available evidence and translate
this into measures of decision uncertainty. For example,
given the findings in Table 3 there is a 60% probability
that aTNFs in combination with MTX result in the
greatest PGA improvements, whereas there is <1% prob-
ability with aTNF as monotherapy being the best. With
aTNF there is ~40% probability that these treatments as
monotherapy rank 6 out of all 8 interventions. The
‘shape’ (or distribution) of these rankograms give an idea
how well the different interventions are doing. The more
the distribution is shifted to the left, the more efficacious
the intervention is relative to its competitors. For pain,
PGA, and HAQ-DI it can be observed that the
rankograms for tocilizumab as monotherapy and in
combination with MTX are comparable, whereas the
rankograms for aTNF as monotherapy and aTNF in
combination with MTX are at opposite ends of the
spectrum: tocilizumab as monotherapy and in combin-
ation with MTX have a comparable efficacy, whereas
aTNF as monotherapy is less efficacious than aTNF with
MTX, which is consistent for the three PROs.
Discussion
RA is a disease that results in a considerable burden for
patients due to pain and functional disability [1]. Hence,
in addition to effectively treating joint inflammation and
reducing the rate of joint deterioration, the aim of treat-
ment is to improve quality of life as well. Since the pa-
tient’s perspective on disease outcomes can be different
from the physician’s perspective, and the impact of dis-
ease on everyday life can only be assessed by the patients
themselves, the evaluation of efficacy of interventions
for RA should also include PROs. In fact, it has been
demonstrated that PROs provide a better discrimination
of the impact of treatment effects on symptoms than
physician-reported outcomes [57-59].
The objective of this study was to compare the efficacy
of different classes of biologic treatments with or with-
out MTX in terms of pain, self-reported disease activity,
functional ability, physical and mental health (SF-36)
and fatigue among DMARD-IR RA patients. Biologic
agents in combination with MTX and as monotherapy
were evaluated simultaneously as part of one network
of RCTs by means of a network meta-analysis and
could therefore be indirectly compared. Both aTNF
and tocilizumab as monotherapy demonstrated greater
reductions in pain, self-reported disease activity
(PGA), and functional ability (HAQ-DI) than placebo.
However, improvements with tocilizumab monother-
apy were greater than aTNF monotherapy in terms of
pain and self-reported disease activity. Tocilizumab was at
least as efficacious as aTNF regarding functional ability




Placebo MTX aTNF Tocilizumab aTNF +MTX Abatacept + MTX Anakinra +MTX Tocilizumab +MTX
Placebo
Estimate 0 14.71 20.17 31.28 32.53 37.63 22.00 30.71
95% CrI (−3.85, 33.43) (12.33, 29.73) (18.69, 45.21) (13.46, 52.09) (6.71, 67.22) (0.86, 42.52) (15.14, 46.97)
P(better) 5% <1% <1% <1% 1% 2% <1%
MTX
Estimate −14.71 0 5.42 16.55 17.85 22.98 7.29 15.97
95% CrI (−33.43, 3.85) (−10.37, 24.07) (3.81, 31.31) (13.02, 23.08) (−1.54, 47.31) (−2.54, 16.69) (6.26, 26.34)
P(better) 95% 22% 1% <1% 3% 5% <1%
aTNF
Estimate −20.17 −5.42 0 11.09 12.40 17.27 1.84 10.60
95% CrI (−29.73, −12.33) (−24.07, 10.37) (0.09, 21.3) (−6.63, 29.01) (−13.17, 45.84) (−19.57, 19.71) (−4.53, 23.59)
P(better) >99% 78% 2% 7% 12% 40% 6%
Tocilizumab
Estimate −31.28 −16.55 −11.09 0 1.30 6.23 −9.29 −0.56
95% CrI (−45.21, −18.69) (−31.31, −3.81) (−21.3, −0.09) (−13.98, 15.15) (−21.98, 33.48) (−27.22, 6.19) (−10.64, 8.41)
P(better) >99% 99% 98% 41% 33% 91% 56%
aTNF + MTX
Estimate −32.53 −17.85 −12.40 −1.30 0 5.06 −10.60 −1.85
95% CrI (−52.09, −13.46) (−23.08, −13.02) (−29.01, 6.63) (−15.15, 13.98) (−19.92, 29.83) (−21.84, −0.05) (−12.93, 9.48)
P(better) >99% >99% 93% 59% 35% 98% 65%
Abatacept + MTX
Estimate −37.63 −22.98 −17.27 −6.23 −5.06 0 −15.61 −6.93
95% CrI (−67.22, −6.71) (−47.31, 1.54) (−45.84, 13.17) (−33.48, 21.98) (−29.83, 19.92) (−42.08, 10.48) (−33.04, 19.51)
P(better) 99% 97% 88% 67% 65% 89% 70%
Anakinra + MTX
Estimate −22.00 −7.29 −1.84 9.29 10.60 15.61 0 8.73
95% CrI (−42.52, −0.86) (−16.69, 2.54) (−19.71, 19.57) (−6.19, 27.22) (0.05, 21.84) (−10.48, 42.08) (−4.56, 23.05)
P(better) 98% 95% 60% 9% 2% 11% 7%
Tocilizumab +MTX
Estimate −30.71 −15.97 −10.60 0.56 1.85 6.93 −8.73 0
95% CrI (−46.97, −15.14) (−26.34, −6.26) (−23.59, 4.53) (−8.41, 10.64) (−9.48, 12.93) (−19.51, 33.04) (−23.05, 4.56)
P(better) >99% >99% 94% 44% 35% 30% 93%























Table 3 Treatment effects for all contrast in terms of patient global assessment (PGA VAS) along with 95% credible interval and probability that treatment is
better than the comparator
Intervention
Comparator
Placebo MTX aTNF Tocilizumab aTNF +MTX Abatacept + MTX Anakinra +MTX Tocilizumab +MTX
Placebo
Estimate 0 14.32 17.35 27.69 33.49 27.98 23.04 29.43
95% CrI (−4.66, 32) (10.63, 25.39) (15.06, 40.53) (14.01, 51.89) (3.21, 50.46) (2.06, 42.8) (13.49, 44.66)
P(better) 5% <1% <1% <1% 2% 2% <1%
MTX
Estimate −14.32 0 2.91 13.22 19.05 13.62 8.72 15.06
95% CrI (−32, 4.66) (−12.59, 21.31) (0.76, 27.44) (14.36, 24.21) (−1.97, 28.4) (−0.37, 17.84) (5.66, 25.14)
P(better) 95% 34% 2% <1% 4% 3% 1%
aTNF
Estimate −17.35 −2.91 0 10.29 16.09 10.60 5.83 12.00
95% CrI (−25.39, −10.63) (−21.31, 12.59) (−0.8, 20.37) (−2.65, 32.53) (−13.52, 31.58) (−15.01, 23.52) (−2.94, 24.98)
P(better) >99% 66% 3% 4% 16% 23% 4%
Tocilizumab
Estimate −27.69 −13.22 −10.29 0 5.76 0.27 −4.46 1.71
95% CrI (−40.53, −15.06) (−27.44, −0.76) (−20.37, 0.80) (−8.91, 19.33) (−20.68, 19.62) (−21.41, 10.72) (−7.84, 10.29)
P(better) >99% 98% 97% 17% 49% 77% 30%
aTNF + MTX
Estimate −33.49 −19.05 −16.09 −5.76 0 −5.40 −10.34 −4.00
95% CrI (−51.89, −14.01) (−24.21, −14.36) (−32.53, 2.65) (−19.33, 8.91) (−22, 10.07) (−20.94, −0.25) (−14.82, 6.97)
P(better) >99% >99% 96% 83% 76% 98% 81%
Abatacept + MTX
Estimate −27.98 −13.62 −10.60 −0.27 5.40 0 −4.86 1.39
95% CrI (−50.46, −3.21) (−28.4, 1.97) (−31.58, 13.52) (−19.62, 20.68) (−10.07, 22) (−22.16, 13.21) (−16.06, 20.05)
P(better) 98% 96% 84% 51% 24% 71% 43%
Anakinra + MTX
Estimate −23.04 −8.72 −5.83 4.46 10.34 4.86 0 6.30
95% CrI (−42.8, −2.06) (−17.84, 0.37) (−23.52, 15.01) (−10.72, 21.41) (0.25, 20.94) (−13.21, 22.16) (−6.65, 20.01)
P(better) 98% 97% 77% 23% 2% 29% 12%
Tocilizumab +MTX
Estimate −29.43 −15.06 −12.00 −1.71 4.00 −1.39 −6.30 0
95% CrI (−44.66, −13.49) (−25.14, −5.66) (−24.98, 2.94) (−10.29, 7.84) (−6.97, 14.82) (−20.05, 16.06) (−20.01, 6.65)
P(better) >99% 99% 96% 70% 19% 57% 88%























Table 4 Treatment effects for all contrast in terms of HAQ-DI along with 95% credible interval and probability that treatment is better than the comparator
Intervention
Comparator
Placebo MTX aTNF Tocilizumab aTNF +MTX Abatacept +MTX Anakinra +MTX Tocilizumab +MTX
Placebo
Estimate 0 0.28 0.37 0.53 0.58 0.49 0.39 0.55
95% CrI (−0.05, 0.62) (0.22, 0.53) (0.27, 0.79) (0.24, 0.93) (0.13, 0.87) (0.02, 0.77) (0.25, 0.86)
P(better) 5% <1% <1% <1% 1% 2% <1%
MTX
Estimate −0.28 0 0.09 0.25 0.30 0.21 0.11 0.27
95% CrI (−0.62, 0.05) (−0.22, 0.39) (0.03, 0.47) (0.22, 0.37) (0.05, 0.37) (−0.05, 0.26) (0.12, 0.42)
P(better) 95% 27% 2% <1% 1% 6% <1%
aTNF
Estimate −0.37 −0.09 0 0.16 0.21 0.12 0.02 0.18
95% CrI (−0.53, −0.22) (−0.39, 0.22) (−0.05, 0.37) (−0.1, 0.52) (−0.21, 0.47) (−0.32, 0.36) (−0.08, 0.44)
P(better) >99% 73% 6% 8% 23% 46% 8%
Tocilizumab
Estimate −0.53 −0.25 −0.16 0 0.05 −0.04 −0.14 0.02
95% CrI (−0.79, −0.27) (−0.47, −0.03) (−0.37, 0.05) (−0.18, 0.28) (−0.3, 0.24) (−0.41, 0.13) (−0.14, 0.18)
P(better) >99% 98% 94% 32% 63% 88% 39%
aTNF + MTX
Estimate −0.58 −0.30 −0.21 −0.05 0 −0.09 −0.19 −0.03
95% CrI (−0.93, −0.24) (−0.37, −0.22) (−0.52, 0.10) (−0.28, 0.18) (−0.26, 0.09) (−0.36, −0.02) (−0.19, 0.14)
P(better) >99% >99% 92% 68% 85% 98% 65%
Abatacept + MTX
Estimate −0.49 −0.21 −0.12 0.04 0.09 0 −0.10 0.06
95% CrI (−0.87, −0.13) (−0.37, −0.05) (−0.47, 0.21) (−0.24, 0.30) (−0.09, 0.26) (−0.33, 0.12) (−0.16, 0.27)
P(better) 99% 99% 77% 37% 15% 84% 28%
Anakinra + MTX
Estimate −0.39 −0.11 −0.02 0.14 0.19 0.10 0 0.16
95% CrI (−0.77, −0.02) (−0.26, 0.05) (−0.36, 0.32) (−0.13, 0.41) (0.02, 0.36) (−0.12, 0.33) (−0.06, 0.37)
P(better) 98% 94% 54% 12% 2% 16% 6%
Tocilizumab +MTX
Estimate −0.55 −0.27 −0.18 −0.02 0.03 −0.06 −0.16 0
95% CrI (−0.86, −0.25) (−0.42, −0.12) (−0.44, 0.08) (−0.18, 0.14) (−0.14, 0.19) (−0.27, 0.16) (−0.37, 0.06)
P(better) >99% >99% 92% 61% 35% 72% 94%























Table 5 Treatment effects for all contrast in terms of SF36-PCS along with 95% credible interval and probability that
treatment is better than the comparator
Intervention
Comparator
MTX Abatacept + MTX aTNF +MTX Tocilizumab +MTX
MTX
Estimate 0 −4.18 −5.24 −4.58
95% CrI (−6.07, −2.27) (−6.33, −4.16) (−5.9, −3.27)
P(better) <1% <1% <1%
Abatacept + MTX
Estimate 4.18 0 −1.08 −0.41
95% CrI (2.27, 6.07) (−3.25, 1.11) (−2.72, 1.87)
P(better) >99% 17% 36%
aTNF + MTX
Estimate 5.24 1.08 0 0.66
95% CrI (4.16, 6.33) (−1.11, 3.25) (−1.04, 2.36)
P(better) >99% 83% 78%
Tocilizumab +MTX
Estimate 4.58 0.41 −0.66 0
95% CrI (3.27, 5.9) (−1.87, 2.72) (−2.36, 1.04)
P(better) >99% 64% 22%
P(better) = Probability that treatment (in row) is showing greater efficacy than comparator (in column); CrI = credible interval; aTNF = Anti-tumor necrosis factor.
Jansen et al. Health and Quality of Life Outcomes 2014, 12:102 Page 10 of 15
http://www.hqlo.com/content/12/1/102(HAQ-DI). In combination with MTX, aTNF, abatacept
and tocilizumab showed comparable improvements in
pain, self-reported disease activity, and physical health as
measured with the SF36-PCS component, whereas aTNF
and tocilizumab showed the greatest improvements in
HAQ-DI. An interesting finding was that aTNFs as mono-
therapy seem less effective than aTNFs in combination
with MTX. With tocilizumab as monotherapy, PROs
similar to that of tocilizumab in combination with
MTX were observed. The difference between aTNF as
monotherapy and aTNF in combination with MTX
can be considered clinically meaningful according to
the defined MCID for pain (10 mm), PGA (10 mm)
and HAQ-DI (0.22).
In addition to pain, self-reported disease activity,
functional ability, and physical health, we aimed to
perform an analysis for fatigue as well. Fatigue is
common in RA [60,61]. Given the differences in fatigue
scales used across studies we did not perform a network
meta-analysis for this endpoint. However, since fatigue is
strongly associated with pain, and secondary associated
with disease activity [62], it can be expected to find a
similar pattern of efficacy across biologics for fatigue
as obtained for pain and PGA.
A limitation of the current analysis is that the study
did not explicitly address differences in risk due to
adverse events among treatments. However, an analysis
of relative short term RCT data would not provide a
valid picture of the adverse event risk associated with
long-term use of biologics. The evidence of efficacy
for all interventions was obtained from RCTs identified
by means of a systematic literature review, which is a
strength from an internal validity point of view. It is
important to realize that the value of randomizationholds within trials but not across trials. As such, there
is the possibility that differences in study and patients
characteristics across studies are modifiers of the
treatment effects. This is a source of heterogeneity
across studies comparing the same interventions, and
a source of bias in the indirect comparison of treat-
ments [29]. There was some variation in duration of
disease, lower swollen and tender joint count, and
CRP across studies, but we did not observe systematic
differences in the distribution of disease duration
across different types of direct comparisons. As such,
these factors can be a cause of heterogeneity (i.e. variation
in true treatment effect across studies within comparison)
but are likely not biasing the indirect comparisons.
Of course, we can never exclude the possibility of
unmeasured differences in patient characteristics across
different comparisons.
Although other network meta-analysis of biologic
treatments for RA have been published in the past few
years [15-22], they focus on clinical outcomes such as
the ACR response rates. This is the first network
meta-analysis that compares the treatment effects of
combination therapy and monotherapy on PROs.
This makes it difficult to compare findings, but highlights
the value of this review in adding to the evidence base.
In addition to this network meta-analysis of PROs, we
recently performed a similar analysis for the ACR 20/50/
70 response outcomes. ACR response is a summary
measure that captures improvement in tender and
swollen joint counts, patient and physician global
assessment of disease, pain, C-reactive protein, and
disability. The findings of that network meta-analysis
were comparable, illustrating that there is not only
consistency across the different PROs, but all also with the
Figure 3 Modeled change in pain, PGA, HAQ-DI and SF36 for
different classes of biologic treatments with and without MTX.
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http://www.hqlo.com/content/12/1/102ACR responses. With the PRO analyses however, the
contrasts in efficacy between aTNF as monotherapy
and combination therapy seem even stronger. The
clinically meaningful differences in pain, PGA and
HAQ-DI between monotherapy and combination therapy
can have important clinical implications. In patients unable
to tolerate MTX, tocilizumab appears to offer a greater
likelihood of PRO improvements than aTNF monother-
apy and may represent an attractive option in this
population.Conclusion
Based on a network meta-analysis involving indirect
comparison of trial findings, the following can be
concluded for DMARD-IR patients: In monotherapy,
tocilizumab was associated with greater improvements
in pain and self-reported disease activity (PGA) than
aTNF, and is at least as efficacious regarding functional
ability (HAQ-DI). The efficacy of aTNF, abatacept and
tocilizumab in combination with MTX were comparable.
Improvements in pain, self-reported disease activity, and
functional ability with tocilizumab as monotherapy were
similar to that of tocilizumab with MTX, whereas aTNF as
monotherapy was likely to be less efficacious than aTNF
with MTX.
Appendix: Search strategy
The following terms were used to search Medline/
EMBASE in April 2012:
1. “randomized controlled trial”.pt.
2. (random$ or placebo$ or single blind$ or double
blind$ or triple blind$).ti,ab.
3. (retraction of publication or retracted publication).
pt.
4. 1 or 2 or 3
5. (animals not humans).sh.
6. ((comment or editorial or meta-analysis or
practice-guideline or review or letter or journal
correspondence) not “randomized controlled trial”).pt.
7. (random sampl$ or random digit$ or random effect
$ or random survey or random regression).ti,ab. not
“randomized controlled trial”.pt.
8. 5 or 6 or 7
9. 4 not 8
10. (random$ or placebo$ or single blind$ or double
blind$ or triple blind$).ti,ab.
11. RETRACTED ARTICLE/
12. 10 or 11
13. (animal$ not human$).sh,hw.
14. (book or conference paper or editorial or letter or
review).pt. not exp randomized controlled trial/
15. (random sampl$ or random digit$ or random
effect$ or random survey or random regression).ti,
ab. not exp randomized controlled trial/
16. 13 or 14 or 15
17. 12 not 16
18. 9 or 17
19. Arthritis, Rheumatoid/
20. rheumatoid arthritis.ti,ab.
21. 19 or 20
22. (adalimumab or Humira).ti,ab.
23. (etanercept or Enbrel).ti,ab.
24. (infliximab or Remicade).ti,ab.
25. (golimumab or Simponi or CNTO 148).ti,ab.
Figure 4 Probability of rank order regarding pain, PGA, HAQ-DI, and SF36 for different classes of biologic treatments with and without MTX.
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http://www.hqlo.com/content/12/1/10226. (certolizumab or Cimzia or CDP870).ti,ab.
27. (tocilizumab or Actemra or RoActemra).ti,ab.
28. (rituximab or Rituxan or Mabthera).ti,ab.
29. (abatacept or Orencia or CTLA-4Ig or CTLA-4Ig).
ti,ab.
30. (anakinra or Kineret).ti,ab.
31. (tumo?r necrosis factor or TNF).ti,ab.
32. (biologic or biological).ti,ab.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32
34. 18 and 21 and 33.
The following terms were used to identify trials from
the Cochrane Controlled Trials Registry in April 2012:
#1. MeSH descriptor Arthritis, Rheumatoid, this term
only
#2. rheumatoid arthritis
#3. (#1 OR #2)
#4. adalimumab or Humira
#5. etanercept or Enbrel
#6. infliximab or Remicade
#7. golimumab or Simponi or CNTO 148
#8. certolizumab or Cimzia or CDP870#9. tocilizumab or Actemra or RoActemra
#10. rituximab or Rituxan or Mabthera
#11. abatacept or Orencia or CTLA-4Ig
#12. anakinra or Kineret
#13. tofacitinib OR tasaocitinib OR CP-690550
#14. tumo*r necrosis factor OR TNF
#15.biologic or biological
#16. (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
OR #11 OR #12 OR #13 OR #14 OR #15).Additional file
Additional file 1: Table S1. Pain, PGA, HAQ-DI and SF36 at 24 weeks as
reported in the individual studies used for the network meta-analysis.Abbreviations
aTNF: Tumor necrosis factor blockers; DMARD: Traditional disease-modifying
anti-rheumatic drugs; DMARD-IR: Inadequate response to conventional
DMARDs; HRQoL: Health related Quality of Life; IL-1: Interleukin-1;
IR: Inadequate response; MTX: Methotrexate; PRO: Patient Reported
Outcomes; RA: Rheumatoid arthritis; RCT: Randomized controlled trial;
HAQ-DI: Health Assessment Questionnaire Disability Index; VAS: Visual analog
scale; MCID: Minimum clinically important differences; PCS: Physical health
component summary; PGA: Patient’s global assessment of disease activity;
MCS: Mental health component summary.
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